Kevin Dunleavy

Amid a U.S. probe into its ties to the Chinese Communist Party (CCP), GenScript has revealed that it is setting up shop in Australia, with a new

Four months after calling for the resignation of four board members from Assertio Holdings, New York investment advisory firm Buxton Helmsley Group has flipped its long equity position into a short interest in Assertio's publicly traded securities.

Azurity Pharmaceuticals has earned FDA approval for Danziten (nilotinib), a new formulation of Novartis' chronic myeloid leukemia (CML) blockbuster

Just three days after Syndax Pharmaceuticals revealed data from a trial of revumenib in one indication of acute leukemia which chilled investors, the FDA has approved the small molecule in another indication of the disease.

As BridgeBio approaches its FDA target date for approval of TTR stabilizer acoramidis to treat the rare heart disease transthyretin amyloid

Two months after Roche scored an FDA approval for its subcutaneous version of PD-LI inhibitor Tecentriq, Merck has achieved a key milestone in lining up its checkpoint inhibitor Keytruda to follow suit.

Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from Chinese news outlets and confirmation from industry sources in the country.

As he introduced Novartis' meet-the-management event Thursday in London, CEO Vas Narasimhan hammered home Novartis' status as a streamlined, “pure-play, innovative medicines” company and the success the new game plan has already produced.

Few pharmaceutical products have taken the market by storm like Roche's Vabysmo. In its first full year on the market, the age-related macular

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the United States, its baby